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Background: Endothelial cell activation and dysfunction are the foundation of atherosclerosis, including coronary
artery disease (CAD). Endothelial cell activation is mediated by the level of gene transcription. Early growth response 3
(Egr3) is a critical determinant of vascular endothelial growth factor (VEGF) signalling in activated endothelial cells. If
endothelial cells are excessively activated, it may lead to vasculopathic diseases, such as pathologic angiogenesis,
inflammation, and atherosclerosis. The aim of the present study was to assess the association between the Egr3 gene
polymorphisms and CAD.
Methods: Two independent case–control studies that involved the Han group (409 CAD patients and 351 control
subjects) and the Uygur group (299 CAD patients and 303 control subjects) analysed the relationship between Egr3
SNPs (rs1996147 and rs1008949) and CAD. Genotyping was undertaken using the TaqMan SNP genotyping assay.
Results: The entire Uygur group and the males in the Uygur group showed a higher frequency of the A allele
(rs1996147) in CAD patients than in the control subjects (P = 0.003 and P = 0.005, respectively). Additionally, the
distribution of the recessive model of rs1996147 (AA vs GG + AG) for the total sample and the males was significantly
different between CAD patients and control participants (P = 0.002 and P = 0.003, respectively), and the difference
remained statistically significant following multivariate adjustment (Total: OR = 1.705; 95% CI: 1.166-2.494, P = 0.006;
males: OR = 1.908, 95% CI: 1.189-3.062, P = 0.007). However, for Uygur females, we did not observe a difference in the
allele frequency or genotypic distribution of rs1996147 between CAD patients and control participants. Similarly, the
distribution of the rs1996147 allele frequency or genotypes showed no significant difference between patients with
CAD and control participants in the Han group. The distribution of rs1008949 genotypes, dominant model, recessive
model, and allele frequency did not show a significant difference between patients with CAD and the control subjects
in the Han and Uygur groups.
Conclusion: rs1996147 may be a novel polymorphism of the Egr3 gene associated with CAD in males of the Chinese
Uygur population.
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Coronary artery disease (CAD) is thought to be a com-
plex multifactorial and polygenic disorder resulting from
interactions between an individual’s genetic makeup and
various environmental factors [1]. Epidemiology investi-
gations have revealed that some genetic variants, such
as polymorphisms in the renin angiotensin system [2],
apolipoprotein E [3], blood coagulation factors [4], and
inflammation factors [5], increase the risk of coronary
artery disease (CAD).
The early growth response (Egr) family of transcription
factors (Egr1 to Egr4) is the nuclear regulator of endo-
thelial cell activation. Egr1, 2, and 3 are transcriptional
activators, whereas Egr4 is a transcriptional repressor.
The activation of target gene transcription by Egr family
members requires their de novo protein synthesis [6].
Egr3 is a member of a zinc finger transcription factor
subfamily, which was found to be strongly upregulated
by vascular endothelial growth factor (VEGF) in an
oligonucleotide microarray screen of endothelial cells
[7]. Recent evidence points to a role for Egr3 in transdu-
cing signals in endothelial cells and is one of the most
highly inducible genes in VEGF–treated endothelial cells
[8,9]. The role of VEGF in atherosclerosis is a subject of
debate in the literature. Some studies show that the ad-
ministration of recombinant human VEGF in animals
enhances the progression of atherosclerotic plaque [10],
whereas others observed that it acts as an anti-
atherosclerotic factor, promoting re-endothelisation, re-
ducing intimal thickening and preventing thrombus
formation [11]. Suehiro and colleagues [6] show that
VEGF-induced endothelial activities are mediated by the
activation of the Egr3 transcription factor. Egr3 is rapidly
induced by extracellular stimuli and has been implicated
in the proliferation and differentiation of several differ-
ent cell types, including endothelial cells [6]. Liu D et al.
[7] reported that VEGF induced a rapid increase in Egr-
dependent transcriptional activation mediated via its
major signalling receptor, tyrosine-kinase receptors KDR
(VEGFR2), and the protein kinase C (PKC) pathway.
The inhibition of Egr3 gene expression by RNA interfer-
ence was effective in inhibiting basal and VEGF-induced
Egr3 gene expression, and it also inhibited VEGF-mediated
endothelial cell proliferation, migration, and tubulogenesis.
These findings indicate that Egr3 has an essential down-
stream role in VEGF-mediated endothelial functions that
lead to angiogenesis and may have particular relevance for
adult angiogenic processes involved in vascular repair and
neovascular disease. However, the role of Egr3 in athero-
sclerosis remains unknown.
Previous studies have shown that the quantification of
amplified Egr3 fragments leads to a significant increase
in expression following 3 h of ischemia, with a max-
imum increase (5-fold) at 24 h in a mouse survivalmodel of ischemia [12]. Therefore, Egr3 may be an im-
portant contributor to the development and progression
of atherosclerotic disease. Accordingly, we screened for
possible mutations and polymorphisms of the Egr3 gene
and assessed the association between the genotypes
of this gene and CAD in a Chinese Uygur and Han
population.
Methods
All patients gave written informed consent and explicitly
provided permission for DNA analyses as well as for the
collection of relevant clinical data. The study protocols
were approved by the Ethics Committees of the First
Affiliated Hospital of Xinjiang Medical University.
Subjects
Two patient populations (Han and Uygur) with CAD were
studied independently. All patients were recruited at the
First Affiliated Hospital of Xinjiang Medical University
from 2007 to 2010. The study participants included 409
Han patients and 299 Uygur patients diagnosed with
CAD. All of the CAD patients were defined by angio-
graphic means (main coronary artery stenosis of >50%).
For each CAD patient group, we selected healthy controls
matched for ethnicity, sex, and age. Control subjects were
selected from the cardiovascular risk survey (CRS) [13,14].
Briefly, the CRS is a prospective, observational cohort
study designed to investigate the prevalence, incidence,
and risk factors of cardiovascular disease in the Han,
Uygur, and Kazakh populations in Xinjiang of China from
October 2007 to March 2010. Control participants in-
cluded Han (n = 351) and Uygur (n = 303) individuals
who did not have coronary vessel stenosis and did
not show clinical or electrocardiographic evidence of
myocardial infarction (MI) or CAD. All patients with
impaired renal function, malignancy, connective tissue
disease, schizophrenia, or chronic inflammatory disease
were excluded. Diabetes, hypertension, hyperlipidemia,
smoking, and alcohol consumption were defined as
previously described [15-17].
Biochemical analysis
We measured the plasma concentration of blood triglyc-
erides (TG), total cholesterol (TC), high-density lipopro-
tein (HDL), and low-density lipoprotein (LDL) using
standard methods in the Clinical Laboratory Department
of the First Affiliated Hospital, Xinjiang Medical Univer-
sity as described previously [17,18].
SNP selection
We selected two single-nucleotide polymorphisms (SNPs)
in the human Egr3 gene as markers for assessment of gen-
etic association. There are 103 SNPs in the human Egr3
gene listed in the National Center for Biotechnology
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Using the Haploview 4.2 software and the HapMap phrase
II database, we obtained two tagging SNPs (rs1996147,
rs1008949) for Chinese Hans and Uygurs using minor al-
lele frequency (MAF) ≥0.05 and linkage disequilibrium
patterns, with r2 ≥ 0.8 as a cut-off.
Genotyping
Blood samples were collected from all participants. Gen-
omic DNA was extracted from peripheral blood leuko-
cytes using phenol and chloroform [19]. Genotyping was
undertaken using TaqMan SNP genotyping assays (Ap-
plied Biosystems [ABI], Foster City, California), which
were performed using Taq amplification [20]. In the first
step of the 5’ nuclease assay, allele-specific fluorogenic
probes were hybridised to the template. Subsequently,
the 5’ nuclease activity of the Taq polymerase made it
possible for discrimination during the polymerase chain
reaction (PCR). The probes contain a 3’minor groove-
binding group that hybridises to single-stranded targets
and has greater sequence specificity than the standard
DNA probes. This reduces nonspecific probe hybridisa-
tion, thereby resulting in low background fluorescence
for the 5’ nuclease PCR assay (TaqMan; Applied Biosys-
tems). Cleavage results in the increased emission of a
reporter dye. Each 5’ nuclease assay requires two un-
labelled PCR primers and two allele-specific probes.
Each probe is labelled with two reporter dyes at the 5’
end. In the present study, VIC and FAM were used as
the reporter dyes. The primers and probes used in the
TaqMan SNP genotyping assays (Applied Biosystems)
were chosen based on information from the ABI website
(http://appliedbiosystems.com.cn/).
PCR amplification was performed using 6 μL of Taq-
Man Universal Master Mix, No AmpErase UNG (2×;
ABI) in a 12-μL final reaction volume containing 2 ng of
DNA, 0.22 μL of TaqMan SNP genotyping assay mix
(20× or 40×), primers at a concentration of 900 nmol/L
each, and probes at a final concentration of 200 nmol/L
each. The thermal cycling conditions were as follows:
50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C
for 15 seconds, and 62°C for 1 minute. Thermal cycling
was performed using the GeneAmp 7900 system. Plates
were read on the sequence detection systems (SDS) auto-
mation controller software v2.4 (ABI).
Statistical analysis
Data analysis was performed using Statistical Package
for Social Sciences SPSS for Windows (version 17.0).
Hardy-Weinberg equilibrium was assessed using X2 ana-
lysis. All continuous variables were expressed as the
mean ± standard deviation (SD). The differences between
the CAD patients and the control participants were
assessed using independent samples t test. Differences inenumeration data between CAD patients and control
participants were analysed using the X2 test. Categorical
variables, such as allele and genotype frequencies among
CAD cases and controls were compared using the chi-
square test. Additionally, logistic regression analysis was
performed to assess the odds ratio (OR) and its 95%
confidence interval (CI) as a measure of the association
between the Egr3 polymorphism and risk of CAD. A
value of P < 0.05 was considered significant.
Results
Table 1 shows the clinical characteristics of CAD pa-
tients and control subjects in the Han population. For
the total sample and for male and female participants,
there were no significant differences in age, body mass
index (BMI), pulse and serum concentration of TG and
HDL-C between patients with CAD and control partici-
pants. For total subjects, males, and females, the follow-
ing values were significantly higher for the CAD patients
compared with the control subjects: LDL-C, incidence
of diabetes, and smoking (all P < 0.05). For total subjects
and males, the serum concentration of total cholesterol
was significantly higher for the CAD patients compared
with the control subjects. However, for females, there
was no difference between CAD patients and control
participants. For males, the prevalence of essential
hypertension (EH) was not significant (P > 0.05); how-
ever, it was higher for patients with CAD than for the
control participants, total subjects and females (P <0.05).
Table 2 shows the clinical characteristics of CAD pa-
tients and control subjects in the Uygur population. For
total subjects, males, and females, the following values
were significantly higher for the CAD patients compared
with the control subjects: the serum concentration of
total cholesterol and LDL-C and smoking (P < 0.05). For
total subjects and male and female participants, there
was no significant difference in the following variables
between CAD patients and control subjects: age, BMI,
pulse, triglycerides, EH, and DM (all P > 0.05). The
serum concentration of HDL-C only showed a signifi-
cant difference between patients with CAD and female
control participants in the Uygur population (P < 0.05).
Tables 3 and 4 show the distribution of the genotypes
and alleles for the two SNPs of Egr3 gene in the Han
and Uygur populations. The genotypic distribution for
each of the SNPs was in agreement with the predicted
Hardy–Weinberg equilibrium values for both ethnicities
(P > 0.05 in the CAD and control groups, data not
shown).
For the total participants in the Uygur group, the dis-
tribution of rs1996147 genotypes showed a significant
difference between patients with CAD and control par-
ticipants (P = 0.003). Additionally, the distribution of
the dominant model (GG vs AA + AG), recessive model















Number of subjects(n) 409 351 300 179 109 172
Age(years), mean(SD) 57.06(10.41) 56.58(9.5) 0.510 56.97(10.89) 56.03(10.05) 0.348 57.64(9.75) 57.16(9.35) 0.680
BMI (kg/m2),mean(SD) 25.60(3.29) 26.06(3.51) 0.060 25.72(3.34) 26.47(3.33) 0.016 25.26(3.13) 25.63(3.66) 0.380
Pulse (beats/min),mean(SD) 72.51(10.90) 72.97(10.28) 0.547 72.19(10.94) 74.09(11.46) 0.072 73.34(10.79) 71.81(8.77) 0.185
Total cholesterol (mmol/L),mean(SD) 4.50(0.91) 4.37(0.99) 0.047* 4.44(0.88) 4.25(1.25) 0.031* 4.68(0.97) 4.46(0.93) 0.058
Triglycerides (mmol/L),mean(SD) 1.84(1.14) 1.77(1.25) 0.483 1.80(1.08) 1.86(1.45) 0.058 1.92(1.30) 1.68(0.99) 0.085
LDL (mmol/L),mean(SD) 2.49(0.91) 2.13(0.83) <0.001* 2.53(0.77) 2.32(0.87) 0.006* 2.47(1.02) 2.03(0.78) <0.001*
HDL (mmol/L),mean(SD) 1.17(0.49) 1.23(0.51) 0.095 1.13(0.51) 1.15(0.54) 0.733 1.26(0.39) 1.31(0.47) 0.374
EH,n (%) 220(53.8) 163(46.4) 0.043* 151(50.3) 80(44.7) 0.232 69(63.3) 83(48.3) 0.014*
DM (%) 102(24.9) 39(11.1) <0.001* 70(23.3) 20(11.2) <0.001* 32(29.4) 19(11.0) <0.001*
Smoking (%) 230(56.2) 87(24.8) <0.001* 208(69.3) 83(46.4) <0.001* 22(20.2) 4(2.3) <0.001*
Continuous variables are expressed as mean ± s.d. Categorical variables are expressed as percentages.
CAD, coronary artery disease; BMI, body mass index; LDL, Low-density lipoprotein; HDL, high-density lipoprotein; EH, essential hypertension; DM, diabetes mellitus.
The P value of the continuous variables was calculated by the independent samples t test.
The P value of the categorical variables was calculated by X2 test. *P < 0.05.
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showed significant differences between patients with CAD
and control subjects (P = 0.018, P = 0.002, and P = 0.001,
respectively). For the males in the Uygur group, the distri-
bution of rs1996147 genotypes, dominant model (GG vs
AA+AG), recessive model (AA vs GG+AG), and allele
frequency of rs1996147 were significantly higher in the
CAD group than in the control participants (P = 0.005,
P = 0.021, P = 0.003, and P = 0.001, respectively). There
was no significant difference between the CAD group
and the control subjects in the Uygur females in the







Number of subjects(n) 299 303
Age (years),mean(SD) 57.32(8.54) 56.78(8.89) 0.447
BMI (kg/m2),mean(SD) 26.05(3.55) 25.89(4.21) 0.615
Pulse (beats/min),mean(SD) 76.06(10.49) 75.02(11.93) 0.212
Total cholesterol (mmol/L),mean(SD) 4.74(0.94) 4.25(0.90) <0.001*
Triglycerides (mmol/L),mean(SD) 1.85(0.95) 1.82(1.12) 0.766
LDL (mmol/L),mean(SD) 2.74(0.81) 2.48(1.12) 0.001*
HDL (mmol/L),mean(SD) 0.99(0.33) 1.06(0.53) 0.054
Hypertension (%) 134(44.8) 123(40.6) 0.295
DM (%) 58(19.4) 41(13.5) 0.052
Smoking (%) 195(65.2) 116(38.6) <0.001*
Continuous variables are expressed as mean ± s.d. Categorical variables are express
LDL, Low-density lipoprotein; HDL, high-density lipoprotein; DM, diabetes mellitus;
samples t test. The P value of the categorical variables was calculated by X2 test. *P(GG vs AA + AG), recessive model (AA vs GG + AG),
and allelic distribution (P > 0.05). Moreover, for total par-
ticipants, males and females in the Uygur group, the dis-
tribution of rs1008949 genotypes, dominant model (CC vs
TT +CT), recessive model (TT vs AA+CT), and allele
frequency did not show significant differences between
patients with CAD and control subjects (P > 0.05). Simi-
larly, for total participants, males and females in the Han
group, the distribution of two SNPs (rs1996147 and
rs1008949), dominant model, recessive model, and allele
frequency showed no significant differences between pa-











198 196 101 107
56.82(8.49) 56.02(8.56) 0.352 58.02(8.62) 57.13(8.96) 0.467
26.29(3.59) 26.11(4.06) 0.641 25.95(3.02) 25.02(4.31) 0.075
75.70(10.51) 74.74(12.80) 0.420 77.08(10.43) 75.52(10.20) 0.278
4.72(0.83) 4.13(0.90) <0.001* 4.77(1.23) 4.45(0.90) 0.023*
1.78(0.93) 1.84(1.08) 0.578 1.98(0.98) 1.80(1.21) 0.233
2.71(0.79) 2.45(1.26) 0.017* 2.80(0.84) 2.53(0.80) 0.019*
0.99(0.33) 1.05(0.63) 0.232 1.01(0.32) 1.09(0.27) 0.039*
86(43.4) 77(39.5) 0.427 48(47.5) 46(43.0) 0.511
38(19.2) 25(12.8) 0.081 20(19.8) 16(15.0) 0.356
145(73.2) 96(49.0) <0.001* 50(49.5) 21(19.6) <0.001*
ed as percentages. CAD, coronary artery disease; BMI, body mass index;
The P value of the continuous variables was calculated by the independent
< 0.05.

















AA 45(11.0%) 49(14.0%) 35(11.7%) 28(15.6%) 10(9.2%) 21(12.2%)
AG 199(48.7%) 156(44.4%) 150(50.0%) 77(43.1%) 49(45.0%) 79(45.9%)
GG 165(40.3%) 146(41.6%) 0.346 115(38.3%) 74(41.3%) 0.252 50(45.8%) 72(41.9%) 0.664
Dominant model
GG 165(40.3%) 146(41.6%) 115(38.3%) 74(41.3%) 50(45.8%) 72(41.9%)
AA + AG 244(59.7%) 205(58.4%) 0.726 185(61.7%) 105(58.7%) 0.515 59(54.2%) 100(58.1%) 0.509
Recessive model
AA 45(11.0%) 49(14.0%) 35(11.7%) 28(15.6%) 10(9.2%) 21(12.2%)
GG + AG 364(89.0%) 302(86.0%) 0.217 265(88.3%) 151(84.4%) 0.213 99(90.8%) 151(87.8%) 0.429
Additive model
AG 199(48.7%) 156(44.4%) 150(50.0%) 77(43.1%) 49(45.0%) 79(45.9%)
AA + GG 210(51.3%) 195(55.6%) 0.246 150(50.0%) 102(56.9%) 0.139 60(55.0%) 93(54.1%) 0.873
Allele
A 289(35.3%) 254(36.2%) 220(36.7%) 133(37.2%) 69(31.7%) 121(35.2%)
G 529(64.7%) 448(63.8%) 0.730 380(63.3%) 225(62.8%) 0.881 149(68.3%) 223(64.8%) 0.390
rs1008949
Genotyping
CC 112(27.4%) 99(28.2%) 85(28.3%) 55(30.7%) 30(27.5%) 44(25.6%)
CT 204(49.9%) 173(49.3%) 149(49.7%) 84(46.9%) 55(50.5%) 89(51.7%)
TT 93(22.7%) 79(22.5%) 0.969 69(23.0%) 40(22.4%) 0.817 24(22.0%) 39(22.7%) 1.000
Dominant model
CC 112(27.4%) 99(28.2%) 85(28.3%) 55(30.7%) 30(27.5%) 44(25.6%)
TT + CT 297(72.6%) 252(71.8%) 0.801 218(72.7%) 124(69.3%) 0.532 79(72.5%) 128(74.4%) 0.719
Recessive model
TT 93(22.7%) 79(22.5%) 69(23.0%) 40(22.4%) 24(22.0%) 39(22.7%)
CC + CT 316(77.3%) 272(77.5%) 0.939 234(77.0%) 139(77.6%) 0.914 85(78.0%) 133(77.3%) 0.995
Additive model
CT 204(49.9%) 173(49.3%) 149(46.7%) 84(46.9%) 55(50.5%) 89(51.7%)
CC + TT 205(50.1%) 178(50.7%) 0.871 154(51.3%) 95(53.1%) 0.633 54(49.5%) 83(48.3%) 0.982
Allele
C 428(52.3%) 371(52.8%) 319(53.2%) 194(54.2%) 115(52.8%) 177(51.5%)
T 390(47.7%) 331(47.2%) 0.838 287(47.8%) 164(45.8%) 0.641 103(47.2%) 167(48.5%) 0.993
CAD, coronary artery disease; SNP, single-nucleotide polymorphism.
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leles for rs1996147 of the Egr3 gene in the Han and Uygur
populations. Both in the CAD patients and in the control
subjects, the distribution of genotype and alleles is signifi-
cantly different in the two ethnic populations (all P < 0.001).
To further investigate the functional role of the
rs1996147 genotypes associated with CAD in the Uygur,
multivariable logistic regression analysis was performed(Table 6). In total subjects and males, following adjust-
ments for the serum concentration of total cholesterol,
LDL-C, and HDL-C, diabetes mellitus, essential hyper-
tension, and smoking, the significance of the recessive
model (AA vs GG +AG) between patients with CAD
and control participants was retained (total: OR = 1.705,
95% CI: 1.166-2.494, P = 0.006; males: OR = 1.908, 95%
CI: 1.189-3.062, P = 0.007).

















AA 109(36.5%) 75(24.7%) 77(38.9%) 49(25.0%) 32(31.7%) 26(24.3%)
AG 142(47.5%) 156(51.5%) 90(45.5%) 98(50.0%) 52(51.5%) 58(54.2%)
GG 48(16.0%) 72(23.8%) 0.003* 31(15.6%) 49(25.0%) 0.005* 17(16.8%) 23(21.5%) 0.433
Dominant model
GG 48(16.0%) 72(23.8%) 31(15.6%) 49(25.0%) 17(16.8%) 23(21.5%)
AA + AG 251(84.0%) 231(76.2%) 0.018* 167(84.4%) 147(75.0%) 0.021* 84(83.2%) 84(78.5%) 0.394
Recessive model
AA 109(36.5%) 75(24.7%) 77(38.9%) 49(25.0%) 32(31.7%) 26(24.3%)
GG + AG 190(63.5%) 228(75.3%) 0.002* 121(61.1%) 147(75.0%) 0.003* 69(68.3%) 81(75.7%) 0.235
Additive model
AG 142(47.5%) 156(51.5%) 90(45.5%) 98(50.0%) 52(51.5%) 58(54.2%)
AA + GG 157(52.5%) 147(48.5%) 0.327 108(54.5%) 98(50.0%) 0.366 49(48.5%) 49(45.8%) 0.694
Allele
A 360(60.2%) 306(50.5%) 244(61.6%) 196(50.0%) 116(57.4%) 110(51.4%)
G 238(39.8%) 300(49.5%) 0.001* 152(38.4%) 196(50.0%) 0.001* 86(42.6%) 104(48.6%) 0.218
rs1008949
Genotyping
CC 118(39.5%) 104(34.3%) 77(38.9%) 66(33.7%) 41(40.6%) 38(35.5%)
CT 136(45.5%) 152(50.2%) 95(48.0%) 98(50.0%) 41(40.6%) 54(50.5%)
TT 45(15.0%) 47(15.5%) 0.409 26(13.1%) 32(16.3%) 0.472 19(18.8%) 15(14.0%) 0.334
Dominant model
CC 118(39.5%) 104(34.3%) 77(38.9%) 66(33.7%) 41(40.6%) 38(35.5%)
TT + CT 181(60.5%) 199(65.7%) 0.191 121(61.1%) 130(66.3%) 0.282 60(59.4%) 69(64.5%) 0.451
Recessive model
TT 45(15.0%) 47(15.5%) 26(13.1%) 32(16.3%) 19(18.8%) 15(14.0%)
CC + CT 254(85.0%) 256(84.5%) 0.875 172(86.9%) 164(83.7%) 0.371 82(81.2%) 92(86.0%) 0.350
Additive model
CT 136(45.5%) 152(50.2%) 95(48.0%) 98(50.0%) 41(40.6%) 54(50.5%)
CC + TT 163(54.5%) 151(49.8%) 0.267 103(52.0%) 98(50.0%) 0.688 60(59.4%) 53(49.5%) 0.153
Allele
C 372(62.2%) 360(59.4%) 249(62.9%) 230(58.7%) 123(60.9%) 130(60.7%)
T 226(37.8%) 246(40.6%) 0.319 147(37.1%) 162(41.3%) 0.227 79(39.1%) 84(39.3%) 0.976
CAD, coronary artery disease; SNP, single-nucleotide polymorphism; *P < 0.05.
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Egr3 is a member of the Egr family, whose members are
rapidly induced by extracellular stimuli and have been
implicated in the proliferation and differentiation of sev-
eral different cell types, including endothelial cells. The
Egr3 gene, located on chromosome 8p21.3, was cloned
from a serum-activated cDNA library [21,22] and was ori-
ginally described as a T-cell receptor–induced cyclosporineA-sensitive factor responsible for the upregulation of
Fas ligand (FasL) [23]. Although Egr3 has been studied
primarily in the context of lymphocyte and neuromus-
cular development, recent evidence points to a role
for Egr3 in transducing signals in endothelial cells. For
example, previous studies [24,25] have shown that Egr3
is one of the most highly inducible genes in VEGF–
treated endothelial cells. Liu D et al. [7] reported that
Table 5 Genotyping and allele distributions in the Han and Uygur population (rs1996147)
CAD patients Control subjects
Variants Han population Uygur population P value Han population Uygur population P value
Genotyping
AA 45(11.0%) 109(36.5%) 49(14.0%) 75(24.7%)
AG 199(48.7%) 142(47.5%) 156(44.4%) 156(51.5%)
GG 165(40.3%) 48(16.0%) <0.001* 146(41.6%) 72(23.8%) <0.001*
Allele
A 289(35.3%) 360(60.2%) 254(36.2%) 306(50.5%)
G 529(64.7%) 238(39.8%) <0.001* 448(63.8%) 300(49.5%) <0.001*
CAD, coronary artery disease; SNP, single-nucleotide polymorphism; *P < 0.05.
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plays an important role in angiogenesis. VEGF is essen-
tial for endothelial cell differentiation and angiogenesis
during development and plays a major role in neovas-
cularisation in a variety of disease states [26]. Lyn D
et al. [12] reported that a cDNA mouse expression
array containing 588 genes representing diverse bio-
logical functions was used to simultaneously compare
changes in gene expression after 24 h of ischemia with
heart tissue from sham-operated mice. The cDNA array
experimental approach provided a global profile of gene
expression changes in the heart ventricle tissue after
coronary artery occlusion. Moreover, the expression of
Egr1 and Egr3 was induced by ischemia. The mechan-
ism by which Egr3 may be associated with CAD re-
mains unclear.
In the present study, there was a significant difference
in the genotypic distribution of rs1996147 between CAD
patients and control subjects in the Uygur. We found
that the Egr3 polymorphisms (rs1996147) were associ-
ated with a risk of CAD in the Uygur population. For
total participants and males in the Uygur group, the A
allele frequency was higher in CAD patients than in con-
trol subjects. This implies that the risk of CAD is in-
creased with the presence of the A allele in the Uygur
population. Similarly, the distribution of the rs1996147
recessive model (AA vs GG +AG) was significantly
higher in the patients with CAD than in the controlTable 6 Multiple logistic regression analysis for CAD patients
Total
Risk factors Odd ratios 95% CI P value O
Recessive model(AA vs GG + AG) 1.705 1.166-2.494 0.006*
DM 1.363 0.85-2.184 0.199
Hypertension 1.209 0.849-1.723 0.293
TC 1.864 1.486-2.338 <0.001*
LDL 1.046 0.856-1.278 0.662
HDL 0.413 0.222-0.766 0.005*
Smoking 2.657 1.877-3.763 <0.001*
CAD, coronary artery disease; DM, diabetes mellitus; TC, total cholesterol; LDL, Low-subjects. The significant difference in the recessive
model between the two groups still existed after the
multivariate adjustment of confounding factors, such as
plasma concentration of TC, HDL and LDL, incidence
of hypertension, diabetes, and smoking. This result indi-
cated that the risk of CAD may increase in Uygur males
with the presence of AA at rs1996147. However, in our
study, Uygur females did not display a difference in the
allele frequency or genotypic distribution between CAD
patients and control participants. This result may be
related to the small sample size of Uygur females. How-
ever, the distribution of rs1996147 genotypes, dominant
model, recessive model, and allele frequency showed no
significant differences between the patients with CAD
and the control participants in the Han group (P > 0.05).
The distribution of rs1008949 genotypes, dominant
model, recessive model, and allele frequency did not
show significant difference between the patients with
CAD and the control subjects in the Han and Uygur
groups. Our study is the first case–control study to in-
vestigate the association between the human Egr3 gene
and CAD in the Uygur and Han in western China.
In conclusion, our study demonstrated that the rs1996147
polymorphism of the Egr3 gene was associated with
CAD in males of the Chinese Uygur population. Males
with the A allele might have a higher risk for CAD than
those with the GG genotype. A larger sample size case–
control study is required to investigate the relationshipand control subjects in the Uygur population (rs1996147)
Men Women
dd ratios 95% CI P value Odd ratios 95% CI P value
1.908 1.189-3.062 0.007* 1.353 0.694-2.637 0.375
1.442 0.787-2.64 0.236 1.288 0.589-2.816 0.525
1.205 0.772-1.88 0.413 1.206 0.666-2.187 0.536
2.268 1.684-3.057 <0.001* 1.415 0.947-2.114 0.09*
1.017 0.806-1.282 0.887 1.122 0.697-1.805 0.636
0.469 0.221-0.99 0.047* 0.354 0.117-1.067 0.065
2.404 1.535-3.062 <0.001* 3.447 1.811-6.559 <0.001*
density lipoprotein; HDL, high-density lipoprotein; *P < 0.05.
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http://www.lipidworld.com/content/13/1/84between the rs1996147 polymorphism of the Egr3 gene
and CAD in females of the Uygur population. Add-
itional studies need to be undertaken to clarify the
underlying molecular mechanism that associates the
Egr3 polymorphisms with CAD.
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